On Nov. 25, 2020, AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Centerﾒs Phase 1/2a study evaluating the two-drug combination of AIMﾒs Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 was fully underway, with the first patient enrolled and treated on the study.